A Medicine Company | Eli Lilly and Company
Lilly is a medicine company that puts health above all. Learn about our medicines, view condition support, find care, and much more.
Eli Lilly and Company - Wikipedia
Eli Lilly and Company ... David Ricks, CEO of Lilly since 2016 Eli Lilly and Company's corporate headquarters in Indianapolis, in 2019 Eli Lilly and Company, doing business as Lilly, is an American …
Lilly moves beyond blockbuster obesity drugs with $1.2 ...
2 days ago · Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the companies said on Wednesday, marking the Zepbound maker's latest push to expand beyond its …
Eli Lilly and Co. | Pharmaceuticals, Biomedical Research ...
Eli Lilly and Company is one of the world’s largest research-based pharmaceutical and biomedical companies,...
Eli Lilly & Co - Company Profile and News - Bloomberg Markets
Jan 2, 2026 · Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company products are sold in countries around the world.
Lilly’s Path to $94B in Revenue Rests on Oral ... - BioSpace
4 days ago · Eli Lilly is on a path to achieving $94.3 billion in annual revenue by 2027, with 2026 serving as a critical year that will define the Big Pharma’s future. Leerink Partners predicted the 109% …
LillyDirect and Walmart Pharmacy Launch ... - Walmart Corporate
Oct 29, 2025 · Key Insights Walmart, with nearly 4,600 pharmacies nationwide, will serve as the first in-store pickup pharmacy for LillyDirect’s self-pay single-dose vials Strategic collaboration marks the …
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Jun 30, 2025 · Eli Lilly is one of the oldest and most storied pharmaceutical companies in the world. Its legacy of breakthroughs has shaped modern medicine: from mass-producing insulin to leading …
Available Medications - Lilly Cares
Frequently Asked Questions (FAQ) What if my medication is not listed or I don't qualify for Lilly Cares?
Lilly returns to Nimbus in $1.3B deal to create oral obesity med
3 days ago · Eli Lilly has returned to Nimbus Therapeutics for another metabolic collaboration, this time focused on the red-hot R&D space of oral obesity therapies.